Charles River Laboratories International, Inc. Stock
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
05:00:02 21/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 314.32 USD | -4.15% |
|
-7.00% | +57.57% |
| Market Cap | 15.06B 13.72B 12.64B 11.5B 21.57B 1,395B 22.67B 154B 61.14B 762B 56.51B 55.32B 2,391B | P/E 2026 * |
35.7x | P/E 2027 * | 33.4x |
|---|---|---|---|---|---|
| Enterprise Value | 17.09B 15.57B 14.34B 13.05B 24.48B 1,583B 25.73B 175B 69.39B 864B 64.13B 62.78B 2,713B | EV / Sales 2026 * |
4.32x | EV / Sales 2027 * | 4.09x |
| Free-Float |
95.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CRL | Delayed | |
| CRL | Real-time | ||
| RV6 | Real-time | ||
| CRL * | End-of-day quote | ||
| RV6 | Real-time | ||
| RV6 | Delayed | ||
| RV6 | Delayed | ||
| RV6 | Delayed | ||
| RV6 | End-of-day quote |
Last Transcript: Charles River Laboratories International, Inc.
| 1 day | -4.15% | ||
| 1 week | -7.00% | ||
| Current month | -12.55% | ||
| 1 month | -0.36% | ||
| 3 months | +7.85% | ||
| 6 months | +101.45% | ||
| Current year | +57.57% |
| 1 week | 310.52 | 343.57 | |
| 1 month | 310.52 | 379.63 | |
| Current year | 146.2 | 379.63 | |
| 1 year | 146.2 | 379.63 | |
| 3 years | 91.86 | 379.63 | |
| 5 years | 91.86 | 385.1 | |
| 10 years | 69.51 | 460.21 |
| Manager | Title | Age | Since |
|---|---|---|---|
Birgit Girshick
CEO | Chief Executive Officer | 56 | 05/05/2026 |
Glenn Coleman
DFI | Director of Finance/CFO | 58 | 06/04/2026 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 12/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 01/01/2000 |
Birgit Girshick
BRD | Director/Board Member | 56 | 05/05/2026 |
Martin MacKay
CHM | Chairman | 69 | 05/05/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/10/26 | Exercice | Director | 72,126 | 0.1511% | ||
| 21/10/26 | Exercice | Executive/Senior Manager | 6,468 | 0.0135% | ||
| 5/10/26 | Exercice | Executive/Senior Manager | 2,943 | 0.0062% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.15% | -7.00% | +93.93% | +64.97% | 15.06B | ||
| -2.49% | -3.76% | +50.31% | +62.10% | 63.66B | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 58.56B | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 54.19B | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 44.66B | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 40.51B | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 36.27B | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 34.89B | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 32.26B | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 31.01B | ||
| Average | -1.65% | -1.47% | +39.69% | +164.23% | 41B | |
| Weighted average by Cap. | -1.58% | -1.92% | +34.42% | +147.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.95B 3.6B 3.32B 3.02B 5.66B 366B 5.95B 40.37B 16.05B 200B 14.83B 14.52B 627B | 4.06B 3.7B 3.41B 3.1B 5.81B 376B 6.11B 41.46B 16.48B 205B 15.23B 14.91B 644B |
| Net income | 423M 385M 355M 323M 606M 39.18B 637M 4.32B 1.72B 21.4B 1.59B 1.55B 67.16B | 431M 392M 362M 329M 617M 39.89B 648M 4.4B 1.75B 21.79B 1.62B 1.58B 68.38B |
| Net Debt | 2.03B 1.85B 1.7B 1.55B 2.91B 188B 3.06B 20.74B 8.24B 103B 7.62B 7.46B 322B | 1.55B 1.41B 1.3B 1.18B 2.22B 143B 2.33B 15.8B 6.28B 78.25B 5.8B 5.68B 246B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/11/26 | US$314.32 | -4.15% | 1,154,126 |
| 19/11/26 | US$327.93 | -1.60% | 495,099 |
| 18/11/26 | US$333.25 | +0.33% | 516,509 |
| 17/11/26 | US$332.16 | -1.00% | 697,548 |
| 16/11/26 | US$335.52 | -0.72% | 693,841 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions
















